Noble Capital Markets Initiates Equity Research Coverage on Nutriband (NTRB)
Noble’s Equity Research Analyst Robert LeBoyer launched coverage on Nutriband today with his report titled “Initiating Coverage With An Outperform Rating And $13 Price Target”
How Trump’s DOGE Initiative Could Reshape Biotech’s Future
The Department of Government Efficiency (DOGE), spearheaded by Donald Trump with the involvement of Elon Musk and Vivek Ramaswamy, promises sweeping changes to federal operations, including deregulation efforts targeting agencies like the FDA. For the biotech industry, these potential reforms could significantly impact drug development, approval processes, and market dynamics.
Noble Capital Markets Served as Co-Manager to Eledon Pharmaceuticals (ELDN) in $85mm Follow-on Offering
Eledon transaction main points.
Noble Capital Markets Initiates Equity Research Coverage on Zomedica Corp. (ZOM)
Noble’s Equity Research Analyst Rober LeBoyer launched coverage on Zomedica Corp. today with his report titled "Improving Pet Health and Veterinary Practices - Initiating Coverage With An Outperform Rating"
Noble Capital Markets Initiates Equity Research Coverage on Perfect Corp. (PERF)
Noble’s Equity Research Analyst Patrick McCann launched coverage on Perfect Corp. today with his report titled "An AI Company Positioned to Accelerate Revenue Growth"
Noble Capital Markets Initiates Research Coverage on Steelcase Inc. (SCS)
Noble's Equity Research Analyst Joe Gomes launched coverage on Steelcase Inc. today with his report titled "A Global Leader with Room to Grow"
Noble Capital Markets Initiates Equity Research Coverage on Vince Holding Corp. (VNCE)
Noble’s Equity Research Analyst Michael Kupinski launched coverage on Vince Holding Corp. today with his report titled “Positioning For a Favorable 2025"
Noble Capital Markets Served as Co-Manager to V2X (VVX) in Secondary Offering of Common Stock
Noble Capital Markets is pleased to announce its role as co-manager in the completion of V2X, Inc.'s recent underwritten underwritten public offering by a certain selling stockholder at the public offering price of $48.00 per share. In connection with the offering, the selling stockholder has granted the underwriters an option to purchase up to 300,000 additional shares of common stock from the selling stockholder. V2X is not selling any shares of common stock in the offering, and V2X will not receive any proceeds from the offering by the selling stockholder.
Noble Capital Markets Initiates Equity Research Coverage on GDEV Inc. (GDEV)
Noble’s Equity Research Analyst Michael Kupinski launched coverage on GDEV Inc. today with his report titled "Why An Upswing In Bookings Matters"
Noble Capital Markets Initiates Equity Research Coverage on FreightCar America
Noble’s Equity Research Analyst Mark Reichman launched coverage on FreightCar America today with his report titled "Poised for Greater Scale and Margin Expansion"
Noble Capital Markets Initiates Equity Research Coverage on Graham Corp. (GHM)
Noble’s Equity Research Analyst Joe Gomes launched coverage on Graham Corp. today with his report titled "Mission Critical Supplier With Solid Growth Prospects"
Noble Capital Markets Initiates Equity Research Coverage on GoHealth Inc. (GOCO)
Noble’s Equity Research Analyst Gregory Aurand launched coverage on GoHealth Inc. today with his report titled "Initiating Coverage: An Encompassing Solution To Improve The Medicare Marketplace"
